Friday, 20 Sep 2019

You are here

Predicting and Preventing Rheumatoid Arthritis

Rheumatologists and physicians are commonly asked, "what can I do to avoid rheumatoid arthritis?"  This is usually a concern for family members of those affected by RA.

However, the answers to this question aren't so clear.  Few patients will inherit RA from a parent or family member. Even monozygotic twins will have less than 20% chance of both developing RA, if one has RA. 

The world's top researchers of the pathogenesis of rheumatoid inflammation (Drs. Klareskog and Holers - along with Dr. Razza) have published a prologue to a series of articles appearing in Rheumatology that will address if we can predict and prevent RA. Specifically, this series will discuss genetic risk factors, the interaction genetic factors and environmental exposures, strategies to predict RA development in at-risk populations, and strategies to prevent RA in those at risk.

They discuss the 5 phases that lead to the development of clinically manifest RA - Genetic/At-Risk,  Environmental exposure, Autoimmune, Early inflammatory, Polyarthritis with established disease. These have led to important investigations in "at-risk" individuals and will soon study if interventions in such people can help to avoid RA onset.

Numerous challenges remain, including: 1) the identification of requisite "triggers", 2) the role of cigarette smoke, toxins, and the microbiota, 3) what is unique and important in those who are seronegative, and 4) are there other disease models we can learn from.

The first article in this series by Karlson et al examines strategies to predict RA onset in at-risk individuals. 

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs. A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).